Cargando…

Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases

BACKGROUND: The clinical and pathological characteristics and the clinical course of patients with breast cancer and BRCA 1–2 mutation are poorly known. METHODS: From 1997, patients with breast cancer and a family history of breast or ovarian cancer were offered BRCA testing. The clinical and pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veronesi, Andrea, Giacomi, Clelia de, Magri, Maria D, Lombardi, Davide, Zanetti, Martina, Scuderi, Cristina, Dolcetti, Riccardo, Viel, Alessandra, Crivellari, Diana, Bidoli, Ettore, Boiocchi, Mauro
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1184063/ https://www.ncbi.nlm.nih.gov/pubmed/15996267 http://dx.doi.org/10.1186/1471-2407-5-70

Ejemplares similares

Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy
por: Miolo, GianMaria, et al.
Publicado: (2006)

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers
por: Miolo, GianMaria, et al.
Publicado: (2009)

Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
por: Veronesi, Andrea, et al.
Publicado: (2010)

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
por: Miolo, Gianmaria, et al.
Publicado: (2014)

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
por: Muraro, Elena, et al.
Publicado: (2011)

Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies
por: Tuzi, Alessandro, et al.
Publicado: (2013)

Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study
por: Mella, Sara, et al.
Publicado: (2017)

Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy
por: Cini, Giulia, et al.
Publicado: (2016)

Molecular and Pathological Features of Gastric Cancer in Lynch Syndrome and Familial Adenomatous Polyposis
por: Fornasarig, Mara, et al.
Publicado: (2018)

Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
por: Muraro, E, et al.
Publicado: (2015)

MUC Gene Abnormalities in Sporadic and Hereditary Mucinous Colon Cancers with Microsatellite Instability
por: Pastrello, Chiara, et al.
Publicado: (2005)

Correlation between chromosome 5q deletions and different mechanisms of c-myc overexpression in human colorectal cancer.
por: Maestro, R., et al.
Publicado: (1991)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
por: Di Lauro, Vincenzo, et al.
Publicado: (2012)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2008)

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers
por: Germani, Aldo, et al.
Publicado: (2020)

Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines.
por: Toffoli, G., et al.
Publicado: (1991)

Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer
por: Miolo, Gianmaria, et al.
Publicado: (2016)

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
por: Hartley, Taila, et al.
Publicado: (2014)

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study
por: Rhiem, Kerstin, et al.
Publicado: (2012)

BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants
por: Concolino, Paola, et al.
Publicado: (2019)

Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA
por: Cangemi, Michela, et al.
Publicado: (2021)

Chromosomal localisation of two putative 11p oncosuppressor genes involved in human ovarian tumours.
por: Viel, A., et al.
Publicado: (1992)

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
por: Girardi, Fabio, et al.
Publicado: (2018)

Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers
por: Rizzolo, Piera, et al.
Publicado: (2018)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype
por: Snell, Cameron, et al.
Publicado: (2008)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases
por: Blanco, Ana, et al.
Publicado: (2013)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

157 Pathogenesis of Epstein-Barr Virus-driven lymphomas of HIV+ patients: new insights of potential clinical relevance
por: Dolcetti, Riccardo
Publicado: (2014)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022)

No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
por: Campbell, Ian G, et al.
Publicado: (2004)

Scar-Free Laparoscopy in BRCA-Mutated Women
por: Restaino, Stefano, et al.
Publicado: (2022)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis
por: Bruno, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qmtu6srvdbfh8cj19qnugv62fo